Supernus Pharmaceuticals Inc (SUPN)
Activity ratios
Short-term
Turnover ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inventory turnover | 7.40 | 4.62 | 4.56 | 4.19 | 4.15 | 5.02 | 5.02 | 5.13 | 5.11 | 5.88 | 5.20 | 4.67 | 4.45 | 5.66 | 5.59 | 5.74 | 5.35 | 5.22 | 5.40 | 7.34 |
| Receivables turnover | 4.66 | 4.50 | 4.15 | 4.05 | 4.21 | 4.37 | 4.70 | 4.70 | 4.07 | 3.97 | 3.91 | 4.04 | 3.76 | 4.08 | 4.02 | 4.22 | 3.60 | 3.50 | 3.31 | 3.37 |
| Payables turnover | 87.61 | 46.27 | 67.14 | 21.87 | 163.46 | 123.56 | 103.37 | 40.54 | 44.34 | 30.54 | 12.41 | 33.64 | 40.98 | 37.30 | 45.15 | 48.40 | 42.09 | 19.80 | 34.58 | 57.35 |
| Working capital turnover | 1.68 | 1.88 | 2.24 | 2.61 | 2.99 | 3.83 | 3.75 | 4.45 | 14.57 | — | — | 2.06 | 1.96 | 1.26 | 1.55 | 1.55 | 1.32 | 1.84 | 1.45 | 1.03 |
Based on the provided data, let's analyze the activity ratios of Supernus Pharmaceuticals Inc:
1. Inventory Turnover Ratio: The inventory turnover ratio measures how efficiently the company manages its inventory. Over the years, Supernus Pharmaceuticals Inc's inventory turnover has shown some fluctuations but generally remained within the range of 4 to 7.40. A higher turnover ratio indicates that the company is selling its inventory quickly, which is positive for cash flow and profitability.
2. Receivables Turnover Ratio: The receivables turnover ratio reflects how well the company collects its accounts receivable. Supernus Pharmaceuticals Inc's receivables turnover has been relatively stable, ranging from 3.31 to 4.70. A higher turnover ratio suggests that the company is efficient in collecting payments from customers.
3. Payables Turnover Ratio: The payables turnover ratio shows how quickly the company pays its suppliers. Supernus Pharmaceuticals Inc's payables turnover has varied significantly over the years, indicating changes in the company's payment policies and relationships with suppliers.
4. Working Capital Turnover Ratio: The working capital turnover ratio measures how effectively the company utilizes its working capital to generate sales. Supernus Pharmaceuticals Inc's working capital turnover has shown some fluctuations, with a notable increase from 2022 to 2023. A higher turnover ratio indicates that the company efficiently converts its working capital into sales revenue.
In conclusion, the analysis of Supernus Pharmaceuticals Inc's activity ratios suggests that the company generally manages its inventory and receivables well. However, there have been fluctuations in payables turnover, indicating changes in payment practices. The working capital turnover has shown improvements, indicating better utilization of working capital to drive sales.
Average number of days
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Days of inventory on hand (DOH) | days | 49.31 | 78.95 | 80.05 | 87.05 | 88.01 | 72.76 | 72.67 | 71.09 | 71.48 | 62.06 | 70.26 | 78.19 | 82.04 | 64.52 | 65.31 | 63.61 | 68.18 | 69.94 | 67.63 | 49.75 |
| Days of sales outstanding (DSO) | days | 78.36 | 81.10 | 87.99 | 90.04 | 86.61 | 83.54 | 77.74 | 77.66 | 89.75 | 91.96 | 93.33 | 90.44 | 97.06 | 89.52 | 90.85 | 86.43 | 101.48 | 104.40 | 110.39 | 108.16 |
| Number of days of payables | days | 4.17 | 7.89 | 5.44 | 16.69 | 2.23 | 2.95 | 3.53 | 9.00 | 8.23 | 11.95 | 29.41 | 10.85 | 8.91 | 9.79 | 8.09 | 7.54 | 8.67 | 18.44 | 10.55 | 6.36 |
The activity ratios for Supernus Pharmaceuticals Inc show fluctuating trends over the years.
1. Days of Inventory on Hand (DOH): This ratio indicates how long it takes for the company to sell its inventory. The trend in DOH fluctuates over the periods, ranging from a low of 49.31 days on December 31, 2024, to a high of 88.01 days on December 31, 2023. Overall, the company seems to have varying levels of inventory management efficiency.
2. Days of Sales Outstanding (DSO): DSO measures the average number of days it takes for the company to collect payment after a sale is made. The trend in DSO also fluctuates, with a low of 77.66 days on March 31, 2023, and a high of 110.39 days on June 30, 2020. The company shows some improvement in collecting payments more quickly in recent periods.
3. Number of Days of Payables: This ratio indicates how long it takes the company to pay its suppliers. The trend in the number of days of payables also varies, ranging from 2.23 days on December 31, 2023, to 29.41 days on June 30, 2022. The company seems to have experienced some challenges in managing its payables efficiently, as evidenced by the variability in this ratio.
Overall, the analysis suggests that Supernus Pharmaceuticals Inc has experienced fluctuations in its activity ratios, indicating potential areas for improvement in inventory management, collections, and payables. Monitoring these ratios consistently can provide valuable insights into the company's operational efficiency and effectiveness in managing working capital.
Long-term
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fixed asset turnover | 57.32 | 55.10 | 51.54 | 46.18 | 44.90 | 45.25 | 45.20 | 46.18 | 44.36 | 41.03 | 37.89 | 34.03 | 33.03 | 33.09 | 32.32 | 14.14 | 13.40 | 26.75 | 23.33 | 22.33 |
| Total asset turnover | 0.48 | 0.49 | 0.48 | 0.46 | 0.48 | 0.48 | 0.50 | 0.38 | 0.40 | 0.38 | 0.36 | 0.36 | 0.33 | 0.35 | 0.35 | 0.36 | 0.34 | 0.31 | 0.28 | 0.34 |
The Fixed Asset Turnover ratio for Supernus Pharmaceuticals Inc has shown a significant upward trend over the years, indicating that the company is utilizing its fixed assets more efficiently to generate revenue. The ratio has increased from 22.33 in March 2020 to 57.32 in December 2024, reflecting a consistent improvement in the company's ability to generate sales from its fixed assets.
On the other hand, the Total Asset Turnover ratio has fluctuated but generally maintained an upward trend from 0.34 in March 2020 to 0.48 in December 2024. This indicates that Supernus Pharmaceuticals Inc is efficiently generating revenue relative to its total assets, although the rate of increase is not as steep as that of the Fixed Asset Turnover ratio.
Overall, the increasing trend in both the Fixed Asset Turnover and Total Asset Turnover ratios suggests that Supernus Pharmaceuticals Inc is effectively managing its assets to drive sales growth and improve its overall operational efficiency.